References
[1] Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012 Sep-Oct; 18(5):411-20.
[2] Cheng Y, Fu Y, Wang Y, Wang J. The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF. Front Genet. 2020 Aug 27; 11:955.
[3] Zhuang YY, Liu HJ, Song X, et al. A Linear Regression Predictor for Identifying N6-Methyladenosine Sites Using Frequent Gapped K-mer Pattern. Mol Ther Nucleic Acids. 2019 Dec 6; 18:673-680.
[4] Roignant JY, Soller M. m6A in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression. Trends Genet. 2017 Jun; 33(6):380-390.
[5] Gao R, Ye M, Liu B, et al. m6A Modification: A Double-Edged Sword in Tumor Development. Front Oncol. 2021 Jul 26; 11:679367.
[6] Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005; 87:163-208.
[7] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33.
[8] Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011:498-505.
[9] Zhu W,Zhao L, Kong B, et al. The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer. Ann Transl Med. 2022 Jan; 10(2):59.
[10] Xie Z, Li M, Hong H, et al. Expression of N6-methyladenosine (m6A) regulators correlates with immune microenvironment characteristics and predicts prognosis in diffuse large cell lymphoma (DLBCL). Bioengineered. 2021 Dec; 12(1):6115-6133.
[11] Zuo S, Dai G, Ren X. Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell Int. 2019 Jan 5; 19:6.
[12] Wang J, Chen L, Qiang P. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer Cell Int. 2021 Feb 10; 21(1):99.
[13] Pu J, Wang J, Qin Z, et al. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism. Front Oncol. 2020 Nov 2; 10:578816.
[14] Cui J, Tian J, Wang W, et al. IGF2BP2 promotes the progression of colorectal cancer through a YAP-dependent mechanism. Cancer Sci. 2021 Oct; 112(10):4087-4099.
[15] Liu H,Qin G,Ji Y,et al.Potential role of m6A RNA methylation regulators in osteosarcoma and its clinical prognostic value.J Orthop Surg Res. 2021 May 5;16(1):294.
[16] Shen S, Yan J, Zhang Y, et al. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Ann Transl Med. 2021 Jan; 9(1):59.
[17] Xu F, Huang X, Li Y, et al. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids. 2021 Apr 9; 24:780-791.